Description
Kusunokinin displays significant activity against intracellular amastigotes (IC(50)=17μM) and trypomastigotes (IC(50)=51μM) without hemolytic activity.
Uses
Kusunokinin ((-)-Kusunokinin) is a nature product that could be isolated form P. nigrum. Kusunokinin has anticancer activity. Kusunokinin arrests cell cycle at G2/M phase and induce apoptosis[1].
in vivo
Kusunokinin ((-)-Kusunokinin; 7 and 14 mg/kg; i.h.; 3 times a week for 2 weeks) attenuates tumor growth in NMU-induced breast cancer rats through the down-regulation of signaling molecules (c-Src, PI3K, Akt and Erk1/2)[1].
| Animal Model: | Female Sprague Dawley rats (7 weeks of age)[1] |
| Dosage: | 7 and 14 mg/kg |
| Administration: | Subcutaneous injection, 3 times a week for 2 weeks |
| Result: | Inhibited the mammary tumor growth and decreased tumor volume.
Down-regulated c-Src, Erk1/2 and PI3K proteins and decreased Akt proteins.
Inhibited downstream molecules in the cell cycle (c-Myc, E2f-1, CDK1 and cyclin B1) and metastasis (E-cadherin, MMP-2 and MMP-9).
|
References
[1] Tedasen A, et, al. (-)-Kusunokinin inhibits breast cancer in N-nitrosomethylurea-induced mammary tumor rats. Eur J Pharmacol. 2020 Sep 5;882:173311. DOI:
10.1016/j.ejphar.2020.173311
![(3R,4R)-3-[(1,3-Benzodioxole-5-yl)methyl]-4-(3,4-dimethoxybenzyl)-4,5-dihydrofuran-2(3H)-one Structure](https://www.chemicalbook.com/CAS/20180906/GIF/58311-20-9.gif)